Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based SGX has submitted an investigational new drug application to the FDA for SGX393.
Subscribe to our email newsletter
This compound is an internally developed, selective, orally-bioavailable small molecule for the treatment of relapsed and refractory chronic myelogenous leukemia.
Mike Grey, CEO of SGX Pharmaceuticals, said: “Filing of this investigational new drug submission represents another testament to our internal capabilities. We continue to focus on moving our discovery and development programs forward.”